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Abstract
During the first weeks of postnatal heart development, cardiomyocytes undergo a major
adaptive metabolic shift from glycolytic energy production to fatty acid oxidation. This meta-
bolic change is contemporaneous to the up-regulation and activation of the p38γ and p38δ
stress-activated protein kinases in the heart. We demonstrate that p38γ/δ contribute to the
early postnatal cardiac metabolic switch through inhibitory phosphorylation of glycogen
synthase 1 (GYS1) and glycogen metabolism inactivation. Premature induction of p38γ/δ
activation in cardiomyocytes of newborn mice results in an early GYS1 phosphorylation and
inhibition of cardiac glycogen production, triggering an early metabolic shift that induces a
deficit in cardiomyocyte fuel supply, leading to whole-body metabolic deregulation and mal-
adaptive cardiac pathogenesis. Notably, the adverse effects of forced premature cardiac
p38γ/δ activation in neonate mice are prevented by maternal diet supplementation of fatty
acids during pregnancy and lactation. These results suggest that diet interventions have a
potential for treating human cardiac genetic diseases that affect heart metabolism.
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Introduction
Adaptation of cardiomyocyte metabolism to heart growth is essential throughout life [1]. Pro-
duction of ATP in fetal cardiomyocytes is highly dependent on glycolysis [2]. Soon after birth,
high-energy demands and increasing levels of circulating non-esterified fatty acids (NEFAs;
also called free fatty acids) trigger a shift in cardiomyocyte metabolism to a predominant reli-
ance on fatty acid oxidation, which consumes more oxygen but also yields more ATP per mol-
ecule than glucose oxidation [3]. This critical metabolic switch from glycolytic to lipolytic
metabolism is a key transition in cardiomyocyte maturation, and deregulation of this process
can affect heart function. For example, deficient cardiomyocyte glycogen storage results in
impaired cardiac function in neonatal animals [4], and disruption of respiratory chain func-
tion during cardiac development compromises the ability of cardiomyocytes to switch their
metabolic profile and reorganize their mitochondria, thus impairing their contractile machin-
ery [5]. Moreover, heart failure (HF) is characterized by a reversion to cardiomyocyte reliance
on glycolysis [6], and it can be induced by a metabolic switch from fatty acid to glucose use in
the adult heart [7]. Hence, a correct control of heart metabolism is essential for maintaining its
functionality, and its deregulation can lead to heart disease.
Glycogen in heart is synthetized by muscle glycogen synthase 1 (GYS1) [8], which is a dis-
tinct isoform from the liver-specific glycogen synthase 2 (GYS2) [9]. GYS1 is regulated by
phosphorylation at multiple sites by several kinases, which lead to its inactivation [10]. Cardiac
glycogen is abundant during prenatal development but declines rapidly after birth, when car-
diomyocytes become dependent on fatty acid metabolism [11,12], suggesting that glycogen
may have a determinant role in heart development and may contribute to proper cardiomyo-
cyte function [11,13]. Although glycogen storage during embryonic development has been
studied, little is known about its function or its regulation during the early postnatal period.
Stress-activated protein kinases (SAPKs) transform extracellular stimuli into a wide range of
cellular processes and are key regulators of tissue homeostasis and metabolism [14]. The
SAPKs p38γ and p38δ (herein referred to as p38γ/δ) promote cardiomyocyte hypertrophic
growth, and their deficiency in mice lead to reduced heart size [15]. Undetectable in the fetal
heart, the expression and activation of p38γ/δ increase in the first 2 weeks after birth [15]—a
crucial period in heart development that requires a tight coordination between cardiac growth
and the metabolic switch.
Here, we report that p38γ/δ control heart metabolism during the early postnatal period of
cardiac development by regulating the activity of GYS1 and glycogen metabolism. We
observed that the gradual up-regulation of p38γ/δ during postnatal development controls the
metabolic switch by inducing GYS1 phosphorylation and inactivation, thereby reducing the
cardiac glycogen storage. Indeed, forced overexpression of cardiomyocyte-specific, active
p38γ/δ on postnatal day 1 (PD1) resulted in premature reduction of glycogen storage as well as
a premature metabolic shift from glycolytic energy production to fatty acid oxidation that trig-
gered maladaptive cardiac pathogenesis. Strikingly, cardiomyocyte metabolic changes led to
altered whole-body homeostasis, including dyslipidemia, hyperglycemia, and insulin resis-
tance. In contrast, mice with cardiomyocyte neonatal-specific deletion of p38γ/δ showed
increased glycogen storage. Depletion of glycogen storage soon after birth by conditional dele-
tion of Gys1 in cardiomyocytes led to perinatal cardiac dysfunction and metabolic changes
similar to the ones observed in the p38γ/δ–overexpressing model. Thus, our study provides
strong evidence that cardiomyocyte p38γ/δ expression and activation after birth are important
regulators of heart glycogen metabolism and are responsible for driving the cardiomyocyte
postnatal metabolic switch. In addition, we demonstrate that premature induction of this met-
abolic switch resulted in cardiac dysfunction and alteration of whole-body metabolism, which
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Results
Premature neonatal activation of p38γ/δ signaling in cardiomyocytes
causes cardiac dysfunction
Cardiac expression of p38γ/δ and their subsequent phosphorylation, which triggers their activa-
tion, is very low at birth and increase postnatally in the first 2 weeks [15] (Fig 1A). This period
coincides with the metabolic adaptations of the fetus/newborn with respect to nutritional transi-
tion and to the cardiomyocyte hypertrophic growth, which requires a higher energy demand
[16]. To understand the role of p38γ/δ in early postnatal cardiac development, we injected mice
with serotype 9 adeno-associated virus (AAV) that overexpressed the constitutively active forms
of p38γ/δ (p38γ/δact) under the control of the cardiac troponin T promoter (TnTp38γ/δact). Car-
diomyocyte-specific overexpression was verified by immunoblot analyses of heart, liver, and
muscle lysates, as well as by immunofluorescence using anti-FLAG antibody in TnTp38γ/δact
cardiac tissue. No signal was detected in liver or muscle from TnTp38γ/δact mice or in heart
from control mice not infected with virus (Fig 1B and 1C, S1 Fig).
To study the effects of premature p38γ/δ expression and activation in cardiomyocytes, we
compared mice injected at PD1 with either TnTp38γ/δact or a control virus encoding luciferase
under the cTNT promoter (AAV-cTnT-GFP-Luc, referred hereafter as TnTGFP). Echocardio-
graphic analyses of PD14 mouse hearts demonstrated eccentric hypertrophy in TnTp38γ/δact
mice as compared to control (TnTGFP) mice, with: (i) thinning of the diastolic interventricu-
lar septum (IVS; d); (ii) thinning of the diastolic left ventricular posterior wall (LVPW; d); and
(iii) an increased left ventricular diameter (LVID; d) (Fig 1D). This cardiac enlargement com-
promised systolic and diastolic function, evidenced by a decreased fractional shortening (FS)
and an increased percentage of mice with abnormal E/A ratios (Fig 1E and 1F). As no differ-
ences were observed between males and females, data were analyzed as a whole (S2 Fig). Gross
anatomic and histologic analyses confirmed these noninvasive findings: TnTp38γ/δact hearts
were larger than control hearts when normalized to tibia length (using heart weight-to-tibia
length (HW/TL)) (Fig 1G and 1H, S3A Fig), and the larger size correlated with an increased
cardiomyocyte cross-sectional area (Fig 1I and 1J). Further histological cardiac examination
revealed fibrosis and altered structure, in line with the systolic and diastolic dysfunction seen
by echocardiography (Fig 1K, S3B and S3C Fig). TnTp38γ/δact were sensitized to myocardial
infarction (MI) and showed greater cardiac dilation and decreased heart function at 4 weeks
after MI, as compared to control mice (S3D Fig). Altogether, premature p38γ/δ activation in
cardiomyocytes of newborn mice led to early eccentric cardiac hypertrophy with decreased
systolic and diastolic function accompanied by cardiac fibrosis, all hallmarks of dilated cardio-
myopathy. Further, this phenotype gave a predisposition for a worse recovery after a cardiac
insult.
Premature cardiomyocyte p38γ/δ activation decreases cardiac glycogen
storage and modulates the postnatal cardiac metabolic switch
As neonatal hearts rely on glycogen metabolism, we first studied whether premature activation
of p38γ/δ in cardiomyocytes affected cardiac metabolism by altering glycogen deposition. Peri-
odic acid–Schiff (PAS) staining and biochemical quantification showed that hearts from
TnTp38γ/δact mice had reduced glycogen as compared to TnTGFP mice (Fig 2A and 2B).
Using these mice, we next evaluated the effects of the reduced glycogen storage. We observed
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that TnTp38γ/δact hearts showed a decreased glycolytic flux, based on the conversion of [3-3H]
glucose into 3H2O that takes place during triose-phosphate isomerase production (Fig 2C).
Notably, the expression levels of multiple enzymes involved in glycolysis were significantly
reduced in hearts from TnTp38γ/δact mice as compared to those from TnTGFP controls (Fig
2D). In agreement with a premature metabolic switch, TnTp38γ/δact hearts presented reduced
heart lipid deposition measured by oil red O (ORO) staining correlating with an increased car-
diac fatty acid oxidation at PD14 as compared to control hearts. This was indicated by the
measurement of 14C-palmitate oxidation through the quantification of the resulting levels of
acid-soluble metabolites (ASMs), which were mainly comprised of acetyl-CoA from incom-
plete β-oxidation (Fig 2E and 2F). A similar tendency was observed for CO2 levels resulting
from radiolabeled palmitate complete oxidation through the TCA cycle (Fig 2F). Quantifica-
tion of cardiac lipids indicated that TnTp38γ/δact hearts have reduced triglycerides (to a large
degree) and diglycerides (to a lesser degree) (Fig 2G). In fact, these hearts presented slightly
increased AMPK and acetyl-CoA carboxylase (ACC) protein levels, suggesting a deficit in car-
diac energy (S4A Fig). However, we did not observe any alterations in the relative abundance
of mitochondrial complexes (measured as total number or activity) (S4B–S4D Fig) or in the
expression of genes involved in lipid metabolism (S4E Fig), suggesting that the metabolic dif-
ferences did not stem from dysfunctional mitochondria but rather from differences in sub-
strate availability. Overall, these results strongly suggest that early p38γ/δ overexpression
produced a change in cardiac fuel, triggering an early metabolic shift from glycolytic energy
production to fatty acid oxidation.
Premature activation of cardiomyocyte p38γ/δ signaling alters whole-body
metabolism
We next studied liver metabolism to determine whether a switch in cardiac fuel use has whole-
body metabolic consequences. We found that livers from TnTp38γ/δact mice at PD14 had a
reduced lipid deposition, as measured by ORO staining (Fig 3A). Concordantly, livers from
TnTp38γ/δact mice showed increased fatty acid oxidation through the TCA cycle as compared
to controls, as indicated by the higher CO2 levels generated upon incubation of liver homoge-
nates with radiolabeled 14C-palmitate. However, no significant differences were observed in
ASM levels generated from incomplete palmitate oxidation (Fig 3B and 3C) or in the expres-
sion or phosphorylation of the metabolic enzymes FAS and AMPK (S5A Fig). Quantification
of hepatic lipids indicated that TnTp38γ/δact livers had reduced triglycerides and NEFAs as
compared with livers from TnTGFP mice at PD14 (Fig 3D). Notably, circulating ketone bod-
ies, which are a feature of failing hearts [17,18], were also elevated in TnTp38γ/δact serum (Fig
3E), although we cannot rule out that they were being used by the heart as a source of energy.
Fig 1. Cardiomyocyte-specific postnatal overexpression of p38γ/δact causes cardiac eccentric hypertrophy and heart dysfunction. (A)
Immunoblot analysis of endogenous p38γ/δ in heart extracts from WT (non-injected) mice at PD 1, 3, 5, 7, 9, and 14. (B) Immunoblot using
anti-FLAG antibody showing p38γ/δact specific cardiac overexpression at PD14 after AAV-cTnT-p38γ/δact injection (at PD1), in heart, liver,
and muscle extracts. (C) Immunofluorescence of FLAG-p38γ/δact (red), WGA (green), and DAPI (blue) on heart sections from WT or
TnTp38γ/δact mice. Scale bar: 200 μm. (D–K) Analyses of hearts at PD14 of AAV-cTnT-GFP-Luc (TnTGFP; control mice) or TnTp38γ/δact
mice (with AAV injection at PD1), showing the following: (D) echocardiography measurements. (E) FS and M-mode short-axis
echocardiography traces; (F) percentage of mice at PD14 with normal or abnormal mitral valve flow (E/A) as an indicator of diastolic
dysfunction; (G) images of whole heart (scale bar: 1 mm) and H&E staining of transverse heart sections (scale bar: 1 mm); (H) HWTL ratio; (I,
J) chart of FITC-WGA staining of hearts (green), with cardiomyocyte cross-sectional area quantification (scale bar: 50 μm); (K) Masson’s
trichrome staining images from heart sections (the respective fibrosis quantification is shown in S1B Fig). Scale bar: 200 μm. Data are
mean ± SEM (n = 5–8). �p< 0.05; ��p< 0.01; ���p< 0.001 by two-tailed Student t test. Raw data are given in S14 Fig. AAV, adeno-associated
virus; FS, fractional shortening; HWTL, heart weight-to-tibia length; H&E, hematoxylin and eosin; IVS; d, interventricular septum thickness
in diastole; LVID; d, left ventricular internal diameter in diastole; LVPW; d, left ventricle posterior wall thickness in diastole; PD, postnatal
day; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3001447.g001
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Fig 2. Cardiac-specific p38γ/δact overexpression decreases cardiac glycogen storage and lipid accumulation. Mice were IV
injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38γ/δ
act) and killed at PD14. (A) PAS staining
in heart sections of TnTp38γ/δact or TnTGFP mice (left) and quantification (right). Scale bar: 200 μm. (B) Cardiac glycogen
quantification. (C) Conversion of [3-3H] glucose into 3H2O, reflecting the glycolytic rate in hearts from TnTGFP and TnTp38γ/δ
act
mice. (D) qRT-PCR analysis of glycolytic enzymes expression in cardiac tissue. (E) ORO staining in heart sections, showing
representative images. Quantification chart below. Scale bar: 50 μm. (F) Cardiac fatty acid oxidation rate of 14C-palmitate
PLOS BIOLOGY Control of cardiac and whole-body metabolism by alternative p38s
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Additionally, blood circulating levels of triglycerides and NEFAs were elevated in TnTp38γ/
δact mice (Fig 3F).
Under severe cardiac stresses, the heart can increase its fatty acid demand by stimulation of
adipose tissue lipolysis [19]. In this regard, we found increased expression of PKA and
increased p38 phosphorylation in white adipose tissue (WAT), both indicative of enhanced
lipolysis [20], that correlated with increased phosphorylation of HSL in Ser660 in TnTp38γ/
δact [21]. No changes in either phosphorylation or expression were detected for ACC or
AMPK (S5B Fig). We therefore evaluated the impact of this cardiac metabolic shift on brown
adipose tissue (BAT) thermogenesis. We found that TnTp38γ/δact mice presented lower BAT
temperatures than TnTGFP mice (Fig 3G). Further, positron emission tomography (PET)
analysis indicated reduced glucose uptake by BAT (Fig 3H), suggesting that cardiac metabolic
requirements in TnTp38γ/δact mice significantly affected BAT functionality. In addition, car-
diac metabolic alterations in TnTp38γ/δ act mice at PD14 led to a reduced body weight and fat
mass (S5C and S5D Fig), suggesting that cardiac premature postnatal overexpression of p38γ/δ
led to cardiomyocyte metabolic reprogramming and affected whole-body lipid metabolism.
We then evaluated the effect on whole-body glucose metabolism and insulin resistance. In
TnTp38γ/δact mice at PD14, cardiac-specific overexpression of p38γ/δ increased blood glucose
levels and insulin resistance (Fig 4A and 4B) but did not change blood insulin levels (S5E Fig).
Increased phosphorylation levels of the serine/threonine kinase Akt upon insulin stimulation
has been used as indicator of tissue insulin sensitivity [22]. We thus analyzed mice at PD14
after injecting with insulin and collected tissues 15 min later. Immunoblot analysis revealed
elevated insulin-stimulated Akt phosphorylation in heart of TnTp38γ/δact mice as compared
to wild-type mice (Fig 4C, S6A Fig), suggesting that reduced glycogen storage might lead to
increased glucose uptake after insulin release. In contrast, insulin-stimulated Akt phosphoryla-
tion was strongly reduced in WAT, muscle, and liver (Fig 4C, S6B–S6D Fig), indicating the
development of insulin resistance in peripheral tissues of TnTp38γ/δact mice (in line with the
higher circulating levels of NEFAs and triglycerides in these mice; see Fig 3G).
To rule out that residual expression of p38γ/δact in muscle under the cTnT promoter was
responsible for the observed systemic metabolic effects, we induced the expression of recombi-
nant active p38γ/δ in newborn mice by injection at PD1 of AAV-Myf4-p38γ/δact (or AAV-My-
f4-EGFP in control mice) and analyzed the mice at PD14 (S7A Fig). Notably, only having
skeletal muscle–specific expression of recombinant active p38γ/δ after birth did not lead to the
whole-body metabolic changes detected in TnTp38γ/δact mice at PD14 (S7B and S7C Fig). We
concluded that cardiac-specific over expression of active p38γ/δ had a profound effect in cardi-
omyocyte metabolism and fuel usage, which triggered substantial whole-body metabolic alter-
ations, including reduced BAT thermogenesis, dyslipidemia, hyperglycemia, and insulin
resistance.
p38γ/δ regulate early postnatal cardiac and whole-body metabolism
During HF, altered cardiomyocyte metabolism and insufficient energy supply can lead to car-
diomyopathy [23]. We therefore analyzed whether the metabolic changes observed in
TnTp38γ/δact hearts at PD14 were secondary to pathological dilated cardiomyopathy or causal
determined by the production of CO2 and ASMs. (G) Cardiac lipid profile. All lipid amounts were normalized by mg of protein
except for NEFAs, which were relativized by mg of tissue. Data are mean ± SEM. (n = 5–12). �p< 0.05; ��p< 0.01; ���p< 0.001 by
Student t test. Raw data are given in S14 Fig. ASM, acid-soluble metabolite; CL, cardiolipin; DG, diglycerides; FC, free cholesterol;
LPC, lysophosphatidylcholine; NEFA, non-esterified fatty acid; ORO, oil red O; PAS, periodic acid–Schiff; PC, phosphatidylcholine;
PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; qRT-PCR, real-time quantitative PCR; TG,
triglyceride.
https://doi.org/10.1371/journal.pbio.3001447.g002
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Fig 3. Cardiac-specific p38γ/δact overexpression has whole-body metabolic consequences. Mice were IV injected at PD1 with AAV-cTnT-GFP-Luc
(TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38γ/δ
act); after metabolic tests were performed at PD14, mice were killed. (A) ORO staining (left) and quantification
(right) of liver sections. Scale bar: 50 μm. (B, C) Hepatic fatty acid oxidation rate of 14C-palmitate, determined by the production of ASMs and CO2. (D)
Hepatic lipid profile. All lipid amounts were normalized by mg of protein except for NEFAs, which were relativized to mg of tissue. (E) Plasma ketone bodies.
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for cardiac disease development. At PD7, TnTp38γ/δact mice had normal-sized hearts with no
fibrosis and showed no signs of eccentric cardiac hypertrophy; however, their cardiomyocytes
already presented low glycogen levels (S8A–S8D Fig). Moreover, these mice had normal car-
diac functions (S8E Fig), albeit with some metabolic alterations (e.g., elevated blood glucose;
S8F Fig) but without changes in circulating triglycerides or NEFA (S8G Fig). This early
(F) Plasma TG and NEFA. (G) Mice BAT temperatures, with its representative thermographic images. (H) BAT glucose uptake measured by PET-CT. Regions
of interest were delimited to the BAT area to obtain the mean SUV. Data are mean ± SEM (n = 7–10). �p< 0.05, ��p< 0.01; ���p< 0.001, by Student t test.
Raw data are given in S14 Fig. ASM, acid-soluble metabolite; BAT, brown adipose tissue; CE, cholesteryl ester; CL, cardiolipin; DG, diglyceride; FC, free
cholesterol; LPC, lysophosphatidylcholine; NEFA, non-esterified fatty acid; ORO, oil red O; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PET-CT,
positron emission tomography–computed tomography; PI, phosphatidylinositol; PS, phosphatidylserine; SUV, standard uptake value; TG, triglyceride.
https://doi.org/10.1371/journal.pbio.3001447.g003
Fig 4. Cardiac-specific p38γ/δact overexpression leads to glucose intolerance and insulin resistance. Mice were treated as for Fig 3. (A) Blood glucose levels. (B) GTT
and ITT. (C) Immunoblot analysis of insulin-stimulated Akt phosphorylation (at Thr308) in heart, WAT, liver, and skeletal muscle. Mice at PD14 were killed 15 min
after IP insulin injection. Data are mean ± SEM (n = 7–10). �p< 0.05; ��p< 0.01; ���p< 0.001 by Student t test or two-way ANOVA coupled to Tukey posttest. Raw
data are given in S14 Fig. GTT, glucose tolerance test; ITT, insulin tolerance test; WAT, white adipose tissue.
https://doi.org/10.1371/journal.pbio.3001447.g004
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appearance of metabolic alterations at PD7 in TnTp38γ/δact mice (e.g., reduced cardiac glyco-
gen storage and altered glucose metabolism) suggested that these changes led to cardiac disease
development.
Premature postnatal activation of p38γ/δ kinases in cardiomyocytes causes
permanent cardiac dysfunction
We next evaluated whether the pathological effects of premature postnatal p38γ/δact expression
persisted in adulthood. Hearts from adult (12-weeks-old) TnTp38γ/δact mice still expressed
exogenous active p38γ and p38δ (Fig 5A, S9A Fig) and exhibited significantly increased left
ventricular fibrosis (Fig 5B and 5C) and systolic dysfunction (Fig 5D). TnTp38γ/δact mice also
had below-normal exercise capacity, as measured by maximum running time and exercise
endurance (S9B Fig). Despite the persistent altered cardiac function, the whole-body metabolic
alterations detected in mice at PD14 were resolved by this stage: adult TnTp38γ/δact mice had
normal ranges of blood glucose levels, glucose tolerance, and insulin sensitivity (Fig 5E and
5F). Moreover, compared to TnTGFP control mice, no changes were detected in plasma
NEFA and triglycerides levels, or cardiac glycogen content (Fig 5G–5I). Thus, premature
p38γ/δ signaling activation in neonatal cardiomyocytes had permanent deleterious effects on
heart function, whereas the deregulated body metabolism resolved once the cardiomyocyte
metabolic shift occurs.
Early postnatal cardiac-specific p38γ/δ deletion increases cardiac glycogen
storage and affects whole-body metabolism
To verify a direct involvement of p38γ/δ in the regulation of cardiac glycogen storage in the
neonatal heart, we evaluated the effects of p38γ/δ deletion with a specific cardiomyocyte
tamoxifen-inducible Cre recombinase system (p38γ/δMyh6Cre). Heart deletion of p38γ/δ was
confirmed after tamoxifen treatment (Fig 6A). p38γ/δMyh6Cre mice at PD14 presented
increased cardiac glycogen levels (Fig 6B–6D). These cardiac effects were associated with
decreased levels of glucose, NEFA, and triglycerides in blood (Fig 6E and 6F). Overall, our data
demonstrated that p38γ/δ kinases control cardiac glycogen storage and highlight that their
dysregulation impacted the whole-body metabolic state.
p38γ/δ phosphorylation of GYS1 promotes GYS1 phosphorylation by
GSK3
GYS1, which is responsible for glycogen synthesis, is inactivated by phosphorylation at its
canonical site Ser641 (p-Ser641) by glycogen synthase kinase-3 (GSK3) [24]. GSK3, in turn, is
activated by phosphorylation by the Akt kinase, which facilitates GSK3’s interaction and phos-
phorylation of its substrates [25]. Of note, in TnTp38γ/δact mice at PD14, the phosphorylation
levels of GYS1 at Ser641 were increased compared with controls, while the phosphorylation
levels of GSK3 and its upstream kinase Akt remained unchanged (Fig 7A). This suggested that
another route besides the canonical phosphorylation pathway led to increased p-Ser641-GYS1
levels. We thus evaluated whether p38γ/δ can directly phosphorylate GYS1 (and act as a prim-
ing site for GSK3) (S10 Fig) in an in vitro kinase assay followed by MS/MS analysis. These
analyses revealed that (i) p38γ alone was not sufficient to phosphorylate GYS1 (at any site); (ii)
p38δ alone phosphorylated GYS1 at Ser723 and Thr278; and (iii) p38γ and p38δ together
phosphorylated GYS1 at 5 residues (Thr84, Thr721, Ser723, Ser727, and Thr278) (Fig 7B,
S11A Fig). Indeed, in HEK-293 cells transfected with GYS1 and constitutively active p38γ and/
or p38δ, GYS1 was phosphorylated at its p38MAPK canonical (Ser/Thr-Pro) residues to a low
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degree when only active p38δ was present, and to a higher degree when both active p38γ and
p38δ were present, as shown by immunoprecipitation and immunoblot analyses (Fig 7C).
Immunoprecipitation of GYS1 protein from HEK-293 transfected cells followed by MS/MS
confirmed that the both kinases together phosphorylated GYS1 at Ser723, Ser727, and Thr278
in vivo, while having either p38γ or p38δ alone, only phosphorylated Ser723 (Fig 7B, S11B and
S11C Fig). Furthermore, immunoprecipitation of p38γ from heart lysates of wild-type (non-
Fig 5. Postnatal cardiac-specific p38γ/δact overexpression leads to heart defects that persist throughout life with no metabolic consequences in
adulthood. Mice were IV injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38γ/δ
act), analyzed for phenotype progression
over 12 weeks, and then killed. (A) Immunoblot analysis of exogenous active (p38γact) and endogenous p38γ in hearts extracts of 12-week-old mice. (B, C)
Masson’s trichrome staining in heart sections from 12-weeks-old mice (B), and quantification (C). Scale bar: 200 μm. (D) Left ventricular FS progression from
weeks 2 to 12. (E) Plasma glucose. (F) GTT and ITT. (G) Plasma NEFA. (H) Plasma triglycerides. (I) Representative PAS staining of heart sections with its
respective quantification relative to TnTGFP mice. Scale bar: 200 μm. Data are mean ± SEM (n = 4–8). �p< 0.05; ��p< 0.01; ���p< 0.001 by two-way
ANOVA coupled to Tukey posttest or Student t test. Raw data are given in S14 Fig. FS, fractional shortening; GTT, glucose tolerance test; ITT, insulin
tolerance test; NEFA, non-esterified fatty acid; PAS, periodic acid–Schiff.
https://doi.org/10.1371/journal.pbio.3001447.g005
Fig 6. Early postnatal cardiac-specific p38γ and p38δ deletion increases cardiac glycogen storage and affects whole body metabolism. Mice were IP
injected with tamoxifen (p38γ/δ Myh6-Cre) or vehicle (Myh6-Cre; control mice) at PD1, PD2, and PD3, and killed at PD14. (A) Immunoblot analysis of p38γ
and p38δ in heart extracts. (B, C) Representative images of PAS staining of heart sections (B) and its quantification, normalized to Myh6-Cre (C). Scale bar:
100 μm and 25 μm (amplification). (D) Glycogen quantification. (E) Blood glucose levels. (F) Plasma triglycerides and NEFA. Data are mean ± SEM (n = 4–6).
�p< 0.05; ���p< 0.001 by Student t test. Raw data are given in S14 Fig. NEFA, non-esterified fatty acid; PAS, periodic acid–Schiff.
https://doi.org/10.1371/journal.pbio.3001447.g006
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infected mice) showed that the cardiac GYS1 protein physically interacts with p38γ, reinforc-
ing the hypothesis that p38γ (and likely p38δ) have a role in regulating the GYS1 protein in the
heart (Fig 7D). Overall, these results suggested that p38γ and p38δ work cooperatively (per-
haps as a complex) to phosphorylate GYS1.
We next evaluated whether phosphorylation of GYS1 residues by p38γ/δ acts as a prim-
ing event to facilitate GSK3 interactions with GYS1 (and thereby promote GYS1 phos-
phorylation at Ser641). A FLAG-pulldown using recombinant FLAG-p38γact or FLAG-
p38δact coprecipitated GYS1 and GSK3 from heart lysates of TnTp38γ/δact mice but not
from control (TnTGFP) mice, indicating that the p38γ and p38δ proteins physically inter-
act in vivo and are part of the same protein complex (Fig 7E). These results suggest that
p38γ/δ might work as a docking platform for mediating the posttranslational modification
of GYS1 by GSK3.
Notably, in TnTp38γ/δact mice, cardiac p38δ coimmunoprecipitated with p38γ (Fig 7F),
further supporting the hypothesis that these 2 proteins form a complex. Furthermore, GYS1
coimmunoprecipitated with p38γ at PD14 from hearts of wild-type mice but not of p38δ−/−
mice (Fig 7G), showing that p38δ was required for a stable GYS1–p38γ interaction. Addition-
ally, increased phosphorylation of GYS1 at Ser641 was only induced if both p38γ/δ kinases
were prematurely activated in cardiomyocytes in neonatal hearts, but not if only one was acti-
vated (using TnTp38γact or TnTp38δact) (S12A Fig).
To further evaluate the possibility that both kinases act in a cooperative manner, we studied
the effects of each kinase alone. Neither TnTp38γact nor TnTp38δact mice at PD14 showed
pathological hypertrophy (Fig 7H) or alterations in heart glycogen deposition (after infection
at PD1) (Fig 7I, S12B Fig). Moreover, glucose and lipid metabolic parameters were unchanged
in TnTp38γact or TnTp38δact mice at PD14 as compared to control mice, except for increased
blood basal glucose levels (S12C–S12E Fig). These data are in concordance with both kinases
being required to phosphorylate and inactivate cardiac GYS1, resulting in reduced cardiac gly-
cogen storage and whole-body metabolic changes.
Postnatal GYS1 deletion leads to whole-body metabolic alterations
We next used the conditional Gys1 mouse line [26] to generate mice with specific cardiomyo-
cyte inducible deletion of GYS1 (Gys1Myh6Cre), to further investigate the effects of the dysregu-
lated p38γ/δ activation on whole-body metabolism. We achieved GYS1 deletion by 3
consecutive tamoxifen IP injections starting at PD1 (Fig 8A). Gys1Myh6Cre mice presented the
following: (i) reduced cardiac glycogen storage and impaired cardiac function (Fig 8B and 8C);
(ii) increased NEFA and glucose circulating levels (Fig 8D and 8E); and (iii) impaired BAT
thermogenesis (Fig 8F and 8G). Altogether, these results suggested that defects in glycogen
Fig 7. p38γ/δ cooperatively interact with GYS1 and GSK3 to promote GYS1 phosphorylation at its canonical site (Ser641). (A) Immunoblot analysis of the
Akt-GSK3–GYS axis in cardiac homogenates from AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38γ/δ
act) mice killed at PD14 with its
respective quantification (lower panel). (B) Scheme showing GYS1 sites phosphorylated by p38γ, p38δ, or both, in an in vitro kinase assay (top, light green) or an
in vivo kinase assay in HEK-293 cells (bottom, dark green). The GYS1 canonical site for GSK3 phosphorylation is Ser641 (shown in bold). Data are
representative of at least 3 independent experiments (biological replicates). (C) In vivo phosphorylation of GYS1 in HEK-293 cells that had been transfected with
Flag-GYS1 alone or together with p38γact or p38δ act, or both. Phosphorylation of transfected GYS1 was evaluated in the Flag-immunoprecipitate with phospho-
MAPK substrates for Ser or Thr. TL before immunoprecipitation is shown as control. (D) Immunoprecipitation and immunoblot analysis of GYS1 and
endogenous p38γ association in WT mice. (E) Immunoblot analysis of GYS1 and GSK3 in Flag-p38γ/δact immunoprecipitates from heart lysates, to detect
interactions between these proteins and the exogenous p38γ/δact. (F) Immunoprecipitation and immunoblot analysis of the association between p38δ and p38γ
in TnTp38γ/δact mice. (G) Immunoprecipitation/immunoblot analysis of the interactions between GYS1 and endogenous p38γ in WT or p38δ−/− mice. (H, I)
Analysis of hearts from mice that were IV injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP), AAV-cTnT-p38γact (TnTp38γ
act), or AAV-cTnT-p38δact
(TnTp38δact) and killed at PD14, showing (H) HWTL ratio and (I) cardiac glycogen content. Data are mean ± SEM (n = 10). One-way ANOVA coupled to
Tukey posttest or Student t test. Raw data are given in S14 Fig. EB, empty bead; GSK3, glycogen synthase kinase-3; GYS1, glycogen synthase 1; HWTL, heart
weight to tibia length; TL, total lysate; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3001447.g007
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cardiac metabolism led to whole-body metabolic alterations, similar to the alterations observed
in TnTp38γ/δact mice.
Maternal HFD feeding suppresses cardiac dysfunction in pups
overexpressing p38γ/δact
Can a metabolic intervention rescue/prevent the deleterious cardiovascular effects of overex-
pressing p38γ/δ (which creates deficient cardiac glycogen storage)? To test this idea, we fed
mouse mothers a high-fat diet (HFD, with 60% kcal derived from fat) starting from pregnancy
confirmation until PD14 of lactating pups (Fig 9A); note that, at PD14, TnTp38γ/δact hearts
show an increased dependency on fatty acids (rather than glycolysis) as an energy source. We
then evaluated pup hearts by echocardiography at PD14, with maternal (M)–normal diet (ND)
or HFD-fed TnTp38γ/δact mothers or M-ND-fed TnTGFP mothers (as a control). Strikingly,
the diastolic function, measured by early (E) to late (A) ventricular filling velocities (E/A), was
normal for the M-HFD-TnTp38γ/δact pups, as compared to the M-ND-TnTGFP (control)
pups, but showed increased frequency of abnormal function for M-ND-TnTp38γ/δact pups
Fig 8. Postnatal GYS1 deletion leads to whole-body metabolic alterations and cardiac dysfunction. Gys1Myh6Cre or Myh6-Cre (control) mice were IP injected
with 62.5 mg/kg tamoxifen at PD1, PD2, and PD3, and killed at PD14. (A) Immunoblot showing partial GYS1 deletion in heart extracts. (B) Heart glycogen
content. (C) Echocardiography-measured FS. (D) NEFA plasma levels. (E) Blood plasma glucose in fed or fasted (e.g., food deprived for 4 h) conditions. (F, G)
BAT temperature chart and representative thermographic images mice at PD14. Data are mean ± SEM (n = 3–17). �p< 0.05; ��p< 0.01; ���p< 0.001 by Student t
test or two-way ANOVA coupled to Tukey posttest. Raw data are given in S14 Fig. BAT, brown adipose tissue; FS, fractional shortening; GYS1, glycogen synthase
1; NEFA, non-esterified fatty acid.
https://doi.org/10.1371/journal.pbio.3001447.g008
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Fig 9. Maternal HFD feeding suppresses cardiac dysfunction in pups overexpressing p38γ/δact. (A) Schematic protocol: CD1 females were crossed; after
pregnancy confirmation by vaginal plug appearance, they were fed a HFD for the entire experiment (e.g., pregnancy and lactation). Neonates were IV injected at
PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38γ/δ
act); during their lactation, mother remained on the same diet (e.g., ND or HFD) as
during pregnancy. Pups were killed at PD14. (B) Percentage of mice at PD14 with normal or abnormal mitral valve flow (E/A) as an indicator of diastolic
dysfunction. (C) Echocardiography measured parameters. (D) BAT temperature chart and representative thermographic images from 2-week-old mice. Data are
mean ± SEM (n = 9 or 10). �p< 0.05, ��p< 0.01, ���p< 0.001 by one-way ANOVA coupled to Tukey posttest or chi-squared test. Raw data are given in S14 Fig.
The figure was prepared using Servier Medical Art (https://smart.servier.com/). BAT, brown adipose tissue; FS, fractional shortening; HFD, high-fat diet; LVID; d,
left ventricular internal diameter in diastole; LV mass, left vetricular mass; LVvol; d, left ventricular volume in diastole; ND, normal diet.
https://doi.org/10.1371/journal.pbio.3001447.g009
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(Fig 9B). Further, heart measurements from M-HFD-TnTp38γ/δact pups were indistinguish-
able to those from M-ND-TnTGFP pups, including diastolic ventricular diameter (LVID;d), left
ventricular volume in diastole (LVvol;d), and FS (indicative of a protection against systolic dys-
function) (Fig 9C). Furthermore, BAT thermogenesis was normal in the M-HFD-TnTp38γ/δact
pups (and impaired in the M-ND-TnTp38γ/δact pups) (Fig 9D). Finally, the cardiac function was
similar between the M-HFD-TnTp38γ/δact and M-ND-TnTGFP pups (S13 Fig). Overall, these
data indicated that M-HFD feeding during pregnancy and lactation prevented the development
of cardiac dysfunction due to premature activation of the p38γ/δ signaling in cardiomyocytes; in
other words, the anatomical and functional consequences of defects in cardiac glycogen storage
and thermogenesis in heart can be metabolically circumvented.
Conclusions
Cardiomyopathies are functional and structural disorders of the heart. In infants, around 5%
to 26% of cardiomyopathies are related to inborn errors of metabolism, with glycogen storage
diseases (GSDs), mitochondrial dysfunction, and lysosomal or fatty acids disorders associated
to cardiac dysfunction in infancy [27,28]. However, genes related to infant cardiomyopathies
must first be identified as a first step for personalized management and therapy [29]. In addi-
tion, a switch in cardiac metabolism appears at the same time that loss of the regenerative
potential of the mammalian heart, suggesting that metabolism controls cell proliferation and
differentiation. Moreover, following injury, the incapacity to regenerate correlates with a meta-
bolic shift from fatty acid oxidation to glycolysis. Thus, understanding the mechanisms that
regulate cardiac metabolism is key to developing metabolic interventions during disease,
regeneration, and development [30].
We have previously shown that p38γ/δ expression is low in cardiomyocytes at birth and
sharply increases during the first 2 weeks of life [15], in parallel with changes in its fuel used by
the heart, from glucose to fatty acid oxidation [15,31]. We have now found that the p38γ/δ kinases
in heart modulate this transition, which is normally associated with cardiomyocyte maturation
during postnatal heart development. Premature expression and activation of cardiac p38γ/δ
resulted in alteration of heart glycogen deposition, which induced severe cardiomyopathy and
altered the whole-body metabolism. Our results demonstrated that early postnatal cardiac expres-
sion and activation of p38γ/δ induced GYS1 phosphorylation at its GSK3 priming site, favoring a
GYS1/GSK3 interaction—and consequentially, GYS1 phosphorylation at Ser641—by GSK3 (Fig
10). We observed that reduction in the cardiac glycogen storage drives cardiomyocyte metabolism
toward a premature use of fatty acids, resulting in decreased cardiac lipid storage and elevated cir-
culating levels of ketone bodies, triglycerides, and NEFAs, which suggests an increased adipose
tissue lipolysis. High lipid demand in heart resulted in deficient BAT thermogenesis in TnTp38γ/
δact mice, possibly due to reduced glucose uptake by this tissue, as shown by PET analyses and an
increased lipid utilization by the heart.
p38γ and p38δ control postnatal heart metabolic switch through GYS1
inactivation
The heart is one of the highest energy consumer organs in mammals and needs high amount
of energy as soon as its first beats in utero. During fetal development, the heart’s energy metab-
olism relies essentially on carbohydrates, and the accumulation of glycogen in cardiomyocytes
serves as a metabolic reserve in order to deal with the increased energy demands. Soon after
birth, the glycogen pool in cardiomyocytes is significantly reduced (approximately 30% of cell
volume in fetal cardiomyocytes, relative to 2% in adult cardiomyocytes), and the energy sub-
strate metabolism rapidly switches to fatty acids oxidation in order to adjust to the new body
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requirements, substrate availability, oxygen pressure and cardiac workload [19]. Various sig-
naling pathways, including insulin through AKT-GSK3 mediated inhibition, the β-adrenergic
cascade through activation of PKA, and AMPK inhibition, have been implicated in the regula-
tion of glycogen storage and fatty acid oxidation [32–35]. Moreover, exposure of cardiomyo-
cytes to oxygen after birth leads to instability of hypoxia-inducible factor (HIF), triggering
mitochondrial biogenesis and activation of lipid oxidation [36]. However, the contribution
and regulation of these pathways during the early postnatal cardiac metabolic switch were not
clear. The biological importance of a timely regulation of cardiac glycogen levels in cardiac
development and function has been highlighted in previous studies in humans and in mouse
Fig 10. Early cardiac p38γ/δ expression inactivates GYS1 affecting cardiac and whole-body metabolism, but the effects can be mitigated by metabolic intervention.
Schematic overview of our findings At early postnatal development, p38γ/δ are not present in heart and in consequence, they did not facilitate GYS phosphorylation and
inactivation by GSK3 allowing glycogen storage. Premature postnatal cardiac-specific p38γ/δ overexpression triggers a premature metabolic switch to fatty acid oxidation,
with whole-body metabolic alterations, including insulin resistance, glucose intolerance, altered hepatic lipid metabolism, and impaired thermogenesis, as well as
permanent cardiac defects. The 2 kinases, p38γ/δ, work collaboratively to control cardiac glycogen storage by regulating GYS1’s interaction with its inhibitory kinase
GSK3. Maternal metabolic intervention by HFD feeding during pregnancy and lactation mitigated the cardiac dysfunction and impaired thermogenesis in offspring,
setting a precedent for treatment of neonatal cardiometabolic genetic diseases. The figure was prepared using Servier Medical Art (https://smart.servier.com/). FAO, fatty
acid oxidation; GSK3, glycogen synthase kinase-3; GYS1, glycogen synthase 1; HFD, high-fat diet.
https://doi.org/10.1371/journal.pbio.3001447.g010
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models, in which alterations in glycogen metabolism genes led to heart disease [37,38]. Disrup-
tion of GYS1 during embryonic development leads to abnormal cardiac development and
function [39]. In addition, impaired glycogen use due to mutations in enzymes involved in gly-
cogen degradation (such as occurs in Pompe disease or GSDIII) has also been associated with
cardiomyopathy and fibrosis, similar to the phenotype we observed in our animals [39–41].
This fibrosis is a hallmark of HF and has been related to cardiomyocyte death and replacement
of lost cardiomyocytes by fibrotic material [42]. Therefore, glycogen metabolism seems to have
a clear role in heart functionality. A better understanding of signaling pathways that regulate
glycogen metabolism in cardiomyocytes has the potential to (i) give insight about underlying
mechanisms of congenital heart disease; (ii) provide new therapeutic targets for infant cardio-
myopathies; (iii) be used for regenerative therapies; and (iv) increase our understanding of
"cardiac flexibility" in adapting to heart injury [43].
Previous work from our laboratory has shown that the alternative SAPKs, p38γ and p38δ,
increase their expression and activity soon after birth, coinciding with the time window of key
metabolic and structural changes that occur in cardiomyocytes [15]. p38γ and p38δ regulate
tissue homeostasis at multiple levels through the phosphorylation of diverse substrates, such as
SAP90, SAP97, and DEPTOR [14,44–46]. Recent evidence suggests that these kinases cooper-
ate in the phosphorylation of some of their substrates [15,47]. Here, we identified a previously
unreported p38γ/δ substrate, GYS1, which is the key enzyme in muscle glycogen synthesis.
p38γ/δ activation during the first weeks after birth leads to GYS1 inhibitory phosphorylation
and reduced glycogen accumulation in heart, at a time when cardiomyocytes switch into fatty
acid oxidation as a main energy source. In vitro and in vivo kinase assays indicated a direct
and cooperative function of p38γ/δ kinases in the phosphorylation of several GYS1 residues
(e.g., Thr278, Ser723, and Ser727). Forced premature induction of p38γ/δ activation in cardio-
myocytes of newborn mice results in reduced cardiac glycogen content due to early GYS1
phosphorylation and inhibition of cardiac glycogen production in vivo. On the other hand,
deletion of these kinases leads to increased cardiac glycogen storage. Our results also suggested
that the p38γ/δ complex acts as a docking platform, thereby coordinating the posttranslational
modification (and inactivation) of GYS1 by GSK3. Further research is required to determine
the exact physiological role of these interactions.
Our previous reports have demonstrated that p38γ/δ can regulate cardiomyocyte hypertro-
phic growth through the activation of the mTOR pathway [15], which has a key role inducing
mitochondrial biogenesis and fatty acids oxidation [48]. Overall, these results suggest that
p38γ/δ kinases may be key regulators of the postnatal metabolic switch, acting not only by
coordinating the inhibition of glycogen storage, but also by promoting fatty acid utilization.
Heart metabolism affects whole-body metabolism
Our findings suggest that cardiomyocytes are key regulators of whole-body metabolism during
early postnatal development, which may be linked to the heart’s high-energy demand at this
stage of rapid growth. Forced premature induction of p38γ/δ activation in cardiomyocytes led
to inhibition of cardiac glycogen synthesis during the first weeks after birth, resulting in an
early metabolic shift to lipid oxidation that induced a deficit in cardiomyocyte fuel supply—
and ultimately, a whole-body metabolic deregulation with increased levels of circulating tri-
glycerides, NEFA, and ketone bodies. We demonstrated that TnTp38γ/δact hearts had
increased rates of fatty acid oxidation; however, it remains to be determined whether these
hearts are also using ketone bodies as an energy source, similar to failing hearts [17,18].
To confirm the link between glycogen synthesis inhibition and whole-body metabolic alter-
ations, we depleted GYS1 specifically in cardiomyocytes during early postnatal development. This
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led to a decreased cardiac function and deregulation of whole-body metabolism—the same phe-
notype obtained when we inactivate GYS1 by overexpressing the kinases p38γ and p38δ. There-
fore, our results demonstrated that cardiac glycogen storage is (i) crucial for the correct cardiac
development in the early postnatal period; and (ii) necessary for the heart’s contractile function.
This highlights the importance of heart as a metabolic tissue in the postnatal period. Mechanisms
underlying the crosstalk between heart and other tissues that affect whole-body metabolism could
involve release of cardiokines. However, the cardiokines identified to date seem to act in an auto-
crine manner to regulate cardiac function and response to stress, with at least 2 examples of cardi-
okines that regulate systemic metabolism: the atrial natriuretic peptide (ANP) and the B-type/
ventricular natriuretic peptide (BNP), both of which lead to browning of WAT [49].
The high fatty acid content of maternal milk in many species effectively provides for the
high energy demand of the newborn heart [50,51]. Moreover, milk triglyceride and insulin lev-
els are elevated in HFD dams at weaning, and they can affect the offspring metabolism [52]. In
addition, HF induced by energy deficits might be prevented by feeding the animals with HFD
[7]. Here, we show that in neonatal mice with premature induction of p38γ/δ activation in car-
diomyocytes, the deficit in cardiomyocyte fuel supply was overcome by increasing the fatty
acid content of maternal milk through maternal HFD feeding. Importantly, this metabolic
intervention by maternal HFD feeding circumvented the cardiac dysfunction in pups. This
provides evidence that the shortage of cardiac glycogen per se was responsible for the cardiac
malfunction and that administration of an alternative lipid energy source can lead to func-
tional recovery. However, since most cardiomyopathies are identified after birth, and most at
later stages, future approaches may confirm the pathological reversion that we have observed.
Of note, HFD interventions are currently used to treat other GSDs, such as GSDIII; however,
there is not much information regarding cardiac impact [41]. Moreover, we showed that HFD
feeding rescued impaired BAT thermogenesis, suggesting that the whole-body metabolic
deregulation also comes from cardiac energy deficiency. Thus, understanding the molecular
regulators of cardiac glycogen storage, and the tissue metabolic demands derived from its defi-
ciency, could be crucial to find a possible treatment for these diseases.
In sum, we identified p38γ/δ as novel regulators of GYS1 activity and cardiac glycogen metab-
olism, highlighting the biological relevance of p38γ and p38δ in cardiac energy metabolism and
function. Importantly, we also demonstrated the importance of cardiac glycogen during the early
postnatal period and the requirement of its presence to guarantee the cardiac functionality and to
maintain correct whole-body metabolism (Fig 10). Our findings may help us to better understand
the mechanisms behind some adult cardiomyopathies with unknown genetic basis, with these
kinases being potential therapeutic targets for treating congenital cardiac metabolic disorders.
Further analysis of the function of these kinases in infant cardiomyopathies, and their role as met-
abolic cardiac regulators in MI and HF, need to be explored. Finally, our results suggest that car-
diac genetic diseases associated with metabolic dysfunction might be treated with maternal diet
intervention, setting a precedent for the treatment of congenital cardiometabolic disorders.
Materials and methods
Mice
Mice deficient for p38γ (B6.129-Mapk12tm1) or p38δ (B6.129-Mapk13tm1) [47] were back-
crossed for 10 generations to the C57BL/6J background (Jackson Laboratory). CD1 mice were
IV injected with 0.5 × 1011 viral particles encoding human p38γ and p38δ active mutants [53]
under the control of the cTNT promoter or the myog promoter, in order to get cardio-specific
or muscle-specific overexpression, respectively. Control mice were injected with virus encod-
ing GFP luciferase.
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For the HFD experiment, pregnant CD1 mice were fed a normal diet containing 22% fat,
28% proteins, and 50% carbohydrates (ND, Altromin, Ref.1410) or a HFD with 60% fat, 20%
protein, and 20% carbohydrates (HFD with 60% kcal derived from fat, of 5% soy bean and
55% lard; D11103002, Research Diets) after positive plug confirmation and maintained during
lactation until pups were killed at PD14.
For the tamoxifen-inducible cardio-specific deletion of both p38γ/δ or GYS1, transgenic
mice B6.FVB(129)-A1cfTg(Myh6-cre/Esr1�)1Jmk/J from Jackson Laboratory [54] were used
to cross with p38γ/δ [55] or GYS1 [26] flox mice. Tamoxifen was injected IP (62.5 mg/kg) for
3 consecutive days starting at PD1. Control mice for the tamoxifen experiments were injected
with corn oil. MI surgeries were performed on PD7. Lateral thoracotomy at the fourth inter-
costal space was performed. A tapered needle attached to a 6–0 prolene suture (Ethicon) was
passed through the midventricle below the origin of the left anterior descending coronary
artery and tied to induce infarction [56]. All experiments were performed in fed condition
unless specified. All animal procedures conformed to EU Directive 86/609/EEC and Recom-
mendation 2007/526/EC regarding the protection of animals used for experimental and other
scientific purposes, enacted under Spanish law 1201/2005. The project was evaluated by the
Research Ethics Committee of the Autonomous University of Madrid (Approval number CEI
94-1704-A275).
Histology
Tissue samples were fixed in 10% formalin for 48 h, dehydrated, and paraffin embedded. Sec-
tions (8 μm) were cut and stained with hematoxylin and eosin (H&E) (American Master Tech
Scientific) or PAS (Sigma). Fat droplets were detected by ORO staining (0.7% in propylene gly-
col) in 8-mm slides in OCT compound (Tissue-Tek). Fibrosis was assessed with Masson’s tri-
chrome staining. PAS, ORO, and Masson’s trichrome staining were quantified as percentage
of stained area in relation to total tissue area using a custom-made macro in ImageJ. PAS was
quantified as percentage of stained area relative to the controls TnTGFP or mhcCre. For wheat
germ agglutinin (WGA) immunofluorescence, 8-μm heart sections were prepared, washed in
PBS 1×, incubated for 2 h in WGA-Alexa 488 lectin (Invitrogen, Carlsbad, California), washed,
and mounted in anti-fade reagent. Four images (20×) were taken from each heart, and the
diameters and areas of 100 to 200 cross-sectionally oriented myocytes were measured and ana-
lyzed with ImageJ. For FLAG immunofluorescence, hearts were harvested and fixed in 4%
paraformaldehyde at 4˚C for 1 h. Tissues were then switched to 10% sucrose/PBS overnight
followed by 18% sucrose/PBS at 4˚C overnight before they were frozen, embedded, and sec-
tioned. For immunostaining, slides were rinsed 3 times in PBS and blocked in 10% goat serum
for 20 min, followed by 3 rinses in PBS. This was followed by overnight incubation with mono-
clonal ANTI-FLAG M2, Clone M2 (F1804, Sigma) primary antibody. The following day, slides
were washed 3 times in PBS and incubated with anti-mouse or anti-rabbit secondary antibod-
ies conjugated (1:400 dilution; Invitrogen) for 1 h. Slides were washed and mounted in anti-
fade reagent.
Glycogen content
Glycogen content was estimated from glucose released, as measured with the Glycogen Assay
Kit (#MAK016, Sigma or ab65620, Abcam). Briefly, glycogen was homogenized in cold water
and then boiled for 5 min as indicated by the manufacturer. Glycogen content was determined
after hydrolyzation, and glucose units were analyzed colorimetrically (570 nm) with an appro-
priate standard curve [57].
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Plasma biochemistry measurements
Mouse serum levels analyses of glucose, triacylglycerides, and NEFAs were performed at UT South-
western Metabolic Phenotyping Core. Serum triacylglycerides and glucose were quantified using a
Vitros 250 clinical analyzer with chemical microslide technology (Ortho-Clinical Diagnosis, Rari-
tan, NJ). NEFA levels in serum were quantified using an in vitro colorimetric method assay (Fuji-
milm Wako Diagnostics USA., Mountain View, CA). Total ketone bodies (acetoacetate [AcAc]
+ 3-hydroxybutyrate [3-HB]) were determined in plasma samples using colorimetric assays from
Wako Diagnostics according to the manufacturer’s protocol (Wako: Autokit total ketone bodies
R1 Set #415–73301; Autokit 3-HB R1 Set#413–73501; and Autokit 3-HB R2 Set#413–73601).
ATP measurement in isolated mitochondria
Mitochondria were extracted from liver [58]. After isolation, mitochondrial protein concentra-
tion was determined by Bradford assay (BioRad), and 10 to 50 μg protein were incubated in
160 μl experimental buffer A (150 mM KCl, 25 mM Tris–HCl, 2 mM EDTA, 0.1% BSA fatty
acid free, 10 mM K-phosphate, 0.1 mM MgCl2 (pH 7.4)), 1 mM substrate, and 20 μl fresh
experimental buffer B (0.5 M Tris-acetate (pH 7.75); 0.8 mM luciferine, 20 mg�ml−1 luciferase).
ATP synthesis was measured using a kinetic luminescence assay, as described in [59] with the
following ATP standard curve: 10, 5, 2.5, 1.25, 0.6, 0.3, 0.15, and 0.075 mM.
Echocardiography
Mice were anesthetized with isoflurane, and echocardiography was performed with a 30-MHz
transthoracic echocardiography probe. Images were obtained with the Vevo 2100 micro-ultra-
sound imaging system (VisualSonics, Toronto, Canada). Short-axis, long-axis, B-mode, and
2D M-mode views were obtained as described [60]. These images were used to calculate inter-
ventricular septum, left ventricular posterior wall thicknesses, and left ventricular corrected
mass; the short-axis M-mode quantification was chosen as the most representative. Cardiac
function was estimated from fractional shortening values that were obtained from M-mode
views by a blinded echocardiography expert. For FS measurements, a long- or short-axis view
of the heart was selected to obtain an M-mode registration in a line perpendicular to the left
ventricular septum and the posterior wall at the level of the mitral chordae tendineae. Normal
E/A ratios were established between 1.2 and 2 for contingency analysis [61,62].
Glucose and insulin tolerance tests
For the glucose tolerance test (GTT), adult mice were fasted overnight, and mice at PD14 were
food deprived for 4 h. Mice were injected intraperitoneally (IP) with 1 g/kg of body weight of
glucose, and blood glucose levels were quantified with an Ascensia Breeze 2 glucose meter at 0,
15, 30, 60, 90, and 120 min postinjection. For the insulin tolerance test (ITT), 0.75 IU/kg of
insulin was given IP to fed mice, and blood glucose levels were measured at 0, 15, 30, 60, 90,
and 120 min postinjection.
Fatty acid oxidation assay
Fatty acid oxidation was assessed as described before [63,64]. Briefly, pieces of fresh liver (30
mg) or heart (30 mg) were homogenized in a Potter homogenizer (5 strokes) in cold buffer (25
mM Tris–HCl, 500 nM sucrose, 1 mM EDTA-Na2 (pH 7.4)) and sonicated for 10 s. Homoge-
nates were centrifuged at 420 g for 10 min at 4˚C. Samples (60 μl) from the homogenate super-
natant were used for the assay, which started by adding 340 μl of assay mixture (500 μM
palmitate/0.4 μCi [1-14C] palmitate per reaction). Samples were incubated for 30 min at 37˚C
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with shaking in tubes with a Whatman filter-paper circle in the cap. The reaction was stopped by
adding 200 μl of 1 M perchloric acid, and 45 μl of 1 M sodium hydroxide was added to impreg-
nate the Whatman cap. After 1 h at room temperature, the Whatman caps (containing released
CO2) were removed, and the radioactivity associated was measured in a scintillation counter.
Tubes were centrifuged at 21,000 g for 10 min at 4˚C, and samples (400 μl) were collected from
the supernatant (containing ASMs). Radioactivity was counted in a scintillation counter.
Protocol for lipid extraction and quantification
Hearts or livers (30 mg) were homogenized in 10 volumes of ice-cold saline buffer in a Potter
homogenizer (20 strokes). Lipids were extracted from 1 mg of protein [65], separated by thin
layer chromatography (TLC) and quantified as described [66]. For quantification, TLC plates
were stained with a solution of 10% CuSO4 (w/v) in 8% H3PO4 (v/v), and an image of the plate
was digitalized with GS-800 densitometer (Bio-Rad Laboratories, USA). Quantification was
performed with Quantity One software (Bio-Rad Laboratories, USA). A part of the lipid
extract was also dissolved in isopropanol (Scharlau Chemicals, Spain), and triglycerides were
measured using a commercial kit (#TK41031 Spinreact) following manufacturer’s protocol.
Immunoprecipitation and immunoblot analyses
For immunoblots, tissue extracts were prepared in Triton lysis buffer (20 mM Tris (pH 7.4),
1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 1
mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 μg/ml each of apro-
tinin and leupeptin). Extracts (20 to 50 μg protein) and immunoprecipitates (prepared from 2
to 10 mg protein) were examined by immunoblot.
For immunoprecipitation assays, heart extracts were incubated with 4 μg of the specific
antibody coupled to protein G-Sepharose beads. After incubation overnight at 4˚C with agita-
tion, the captured proteins were centrifuged at 10,000 g, supernatants collected, and beads
washed 4 times in lysis buffer. Beads were then boiled for 5 min 95˚C in 10 μl of Laemli buffer.
Extracts and immunoprecipitates were examined by SDS-PAGE and blotted with antibodies
to the following targets: p38γ or p38δ [44,67]; p38δ (#sc7585, Sta. Cruz), β-actin (#sc-47778,
Sta. Cruz), GAPDH (#sc-25778, Sta. Cruz), vinculin (#V9131, Sigma), FLAG (#F1804, Sigma);
phospho-threonine-proline (#9391S), phospho-serine-proline (#2325S), phospho-Akt
(Thr308) (#2965S), Akt (#9272S), phospho-GSK3α/β (Ser21/9) (#9327S), GSK3β (#9315S),
phospho-Gys (Ser641) (#3891S), phospho-ACC (Ser79) (#3661S), ACC (#3676S), hormone–
sensitive lipase (HSL, #4107S), phospho-HSL (Ser660) (#4126S), Fatty acid synthase (FAS,
#3189S), p-PKA C (Thr197) (#4781S), PKA C α (#4782S), phospho-AMPK (thr172) (#2535S),
AMPKα (#2603S), p38γ (#2307S), phospho-p38 (T180/Y182) (#9211S), or Gys1 (#3893S) (Cell
Signaling). Mitochondrial complexes were assayed using Total OXPHOS Rodent WB Anti-
body Cocktail (ab 110413). Secondary antibodies were purchased from Invitrogen. Immuno-
complexes were detected by enhanced chemiluminescence (GE Healthcare Lifesciences).
Cell lines and cell culture
HeLa and HEK-293T cells were cultured in DMEM supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Sigma), glutamine (2 mM), and penicillin/streptomycin (100 μg/ml).
Adeno-associated virus (AAV) vector production and cell infection
AAV vector production, purification, and verification were performed as described [68]. All
AAV vectors were produced by the triple transfection method, using HEK293A cells. AAV
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plasmids were cloned and propagated in the Stbl3 E. coli strain (Life Technologies). AAV plas-
mids were packaged into AAV-9 capsids with the use of the helper plasmids pAdDF6 (provid-
ing the 3 adenoviral helper genes) and pAAV2/9 (providing rep and cap viral genes), obtained
from PennVector. Shuttle vectors were generated by direct cloning (GeneScript) of synthesized
NheI-SalI fragments into pAcTnT or pmyog cut with the same restriction enzymes.
The AAV shuttle and helper plasmids were transfected into HEK293A cells by calcium
phosphate coprecipitation. A total of 840 μg plasmid DNA (mixed in an equimolar ratio) was
used per Hyperflask (Corning) seeded with 1.2 × 108 cells the day before. At 72 h after transfec-
tion, cells were collected by centrifugation, and the cell pellet was resuspended in TMS (50
mM Tris–HCl, 150 mM NaCl, 2 mM MgCl2) on ice before digestion with DNase I and RNase
A (0.1 mg/ml each; Roche) at 37˚C for 60 min. Clarified supernatant containing the viral parti-
cles was obtained by iodixanol gradient centrifugation. Gradient fractions containing virus
were concentrated using Amicon UltraCel columns (Millipore) and stored at −80˚C. Known
copy numbers (1 × 105–108) of the respective plasmid carrying the appropriate complementary
DNA were used to construct standard curves.
Intensity-controlled treadmill running
The exercise capacity test was modified from Kemi and colleagues [69]. Adult (12-week-old)
TnTGFP or TnTp38γ/δact mice underwent a 20-min regular warm-up before they ran at fixed
submaximal velocities of 0.15, 0.20, or 0.25 m/s at 25˚ inclination for 5 min at each velocity. The
treadmill velocity was then increased by 0.03 m/s every 2 min until the mice were unable, or
refused, to run further upon subtle electric stimulations located at the beginning of the treadmill
platform; the total running time duration and total distance were recorded for each mouse [69].
cDNA transfection-based experiments
Cells were plated at 60% confluence in DMEM/10% FBS at 12 to 15 h before transfection. Cells
were transfected using the calcium phosphate method [70] with the cDNA expression plas-
mids indicated in Fig 7B and 7C and S11B and S11C Fig. The culture medium was replaced 12
h after transfection with fresh complete medium, and cells were harvested 48 h later. The plas-
mids used in the different experiments were pCEFL FLAG p38 gammaD129A and pCMV FLAG
p38 deltaF324S (kindly provided by David Engelberg, The Hebrew University of Jerusalem,
Israel).
In vitro kinase assay
Human GYS1 protein (1 μg) (DV-43557, DSTT, Dundee) was incubated with 1 μg of active
recombinant p38γ and/or p38δ (provided by the MRC Protein Phosphorylation and Ubiquity-
lation Unit, Dundee, UK) in the presence of 200 μM cold ATP for 30 min. The reaction was
stopped by adding SDS-containing sample buffer, and proteins were resolved by SDS-PAGE
and visualized by staining with colloidal Coomassie Blue. The band containing GST-GYS1 was
excised and treated with DTT to reduce disulfide bonds, and with iodoacetamide to derivatize
cysteine residues. The protein was in-gel digested with trypsin, and the resulting peptides were
extracted from the gel and analyzed by nanoscale-microcapillary reversed-phase liquid chro-
matography–tandem mass spectrometry (LC–MS/MS) [71,72].
In vivo kinase assay
HEK293 were transfected with human FLAG-GYS1 alone or together with p38γact, p38δ act, or
both, using the calcium phosphate transfection method [70]. Cells were harvested 48 h after
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transfection, and tissue extracts were prepared in Triton lysis buffer (20 mM Tris (pH 7.4), 1%
Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 1 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml each aprotinin and leu-
peptin). Total protein concentrations were quantified with Bradford assay, and 3 mg of total
protein were incubated with 2 μg of monoclonal ANTI-FLAG M2, Clone M2 (F1804, Sigma)
coupled to 50 μl Protein G Dynabeads (Thermo Fisher) per experimental condition. After 2 h of
incubation at 4˚C with agitation, beads were washed 4 times in lysis buffer and heated for 5 min
at 95˚C in 20 μl sample buffer, and proteins were resolved by SDS–PAGE. For visualization, gels
were stained with colloidal Coomassie Blue, and the GYS1 gel bands were excised. The band
containing Flag-GYS1 was treated with DTT to reduce disulfide bonds, and with iodoacetamide
to derivatize cysteine residues. The protein was in-gel digested with trypsin, and the resulting
peptides were extracted and analyzed by nanoscale-microcapillary LC–MS/MS.
Positron emission tomography (PET)
For the PET-CT acquisition, mice were anesthetized using isoflurane and oxygen. Ophthalmic
gel was placed in the eyes to prevent drying. PET-CT studies were performed with a small-ani-
mal PET/CT scanner (nanoScan, Mediso, Hungary). CT study was acquired 60 min after intra-
peritoneal administration of 8 to 10 MBq of [18F]FDG using an X-ray beam current of 178 μA
and a tube voltage of 45 kVp. After the CT scan, PET data were collected for 15 min and recon-
structed using Teratomo 3D algorithm, in a 105 × 105 × 235 matrix (voxel dimensions of 0.4
mm). Regions of interest (ROIs) were delimited for the brown fat (BAT) to obtain the mean
standard uptake value (SUVmean).
Determination of glycolytic flux
The glycolytic flux was estimated by determining the rate of conversion of D-[3-3H]glucose into
3H2O, which, as previously validated [55], assesses the rate of
3H of C3-glucose interchange
with water at triose-phosphate isomerase [73]. In essence, heart slices (10 to 40 mg) were prein-
cubated for 1 h in 2 ml of a Krebs–Henseleit buffer (11 mM Na2HPO4, 122 mM NaCl, 3.1 mM
KCl, 0.4 mM KH2PO4, 1.2 mM MgSO4, 1.3 mM CaCl2; pH (7.4) supplemented with 5.5 mM D-
glucose at 37˚C, followed by incubation in the presence of 5 μCi/ml of D-[3-3H]glucose in fresh
Krebs–Henseleit buffer (2 ml) in glass 25-ml Erlenmeyer flasks equipped with a central well
containing a tube with 0.5 ml of water. The flask atmosphere was gassed with a O2/CO2 (95/5)
mixture for 20 s and stopped with a rubber cap, and the flasks were incubated in a thermosta-
tized orbital shaker (Forma Benchtop Orbital Shaker, Model 420, Thermo Fisher) for 4 h at
37˚C. 3H2O collected in the tube placed in the central well was linear with time up to at least 4
h. Incubations were finished by injecting 0.2 ml of 20% (v/v) HClO4 through the rubber cap,
and flasks were further incubated for 72 h to allow the equilibration of 3H2O between the incu-
bation medium and the water of the central well. The rate of glycolysis was expressed as nmol of
D-[3-3H]glucose incorporated into 3H2O per h and per mg tissue.
Temperature
BAT-adjacent interscapular temperature was quantified by thermographic images using a FLIR
T430sc Infrared Camera (FLIR Systems, Wilsonville, OR) and analyzed through FlirIR software.
Nuclear magnetic resonance analysis
Body, fat, and lean mass were quantified by nuclear magnetic resonance (Whole Body Compo-
sition Analyzer; EchoMRI, Houston, TX) and analyzed by ImageJ software.
PLOS BIOLOGY Control of cardiac and whole-body metabolism by alternative p38s
PLOS Biology | https://doi.org/10.1371/journal.pbio.3001447 November 10, 2021 25 / 34
qRT-PCR
Expression of mRNA was examined by qRT-PCR using a 7900 Fast Real Time thermocycler
and FAST SYBR GREEN assays (Applied Biosystems). Relative mRNA expression levels of
Pparα, Pppargc1α, Cpt1α, Cpt1β, Acox1, Lpl, Dagt2, Elov6, Hk2, Pepck, Ldha, Pkm2 and Glut4,
were normalized to Gapdh mRNA measured in each sample.
The number of mitochondria was assessed by estimating the mitochondrial-to-chromo-
somal DNA ratio. The mitochondrial genes Citb, Cox1, and Nd1 were normalized to genomic
Lpl. Primer sequences are shown in Table 1.




































FW, forward primer; REV, reverse primer.
https://doi.org/10.1371/journal.pbio.3001447.t001
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Statistical analysis
Between-group differences were examined for statistical significance by two-tailed Stu-
dent t test, or one-way or two-way ANOVA coupled to Tukey posttest, as indicated. Chi-
squared tests were performed for categorical data. Error bars represent standard error
mean (SEM).
Supporting information
S1 Fig. Mean intensity quantification of FLAG immunofluorescence in WT and TnTp38γ/
δact hearts (Fig 1C) using ImageJ. Data are mean ± SEM (n = 4–5). ���p< 0.001 by Student t
test. Raw data are given in S14 Fig. WT, wild-type.
(TIF)
S2 Fig. Cardiac-specific p38γ/δ overexpression induce functional and geometrical changes
in both male and female mice. Echocardiography analyses of hearts at PD14 from AAV-
cTnT-GFP-Luc (TnTGFP; control mice) or TnTp38γ/δact mice (with AAV injection at PD1).
Data are mean ± SEM. (n = 6–8). �p< 0.05, ��p< 0.01, ���p< 0.001 by Student t test. Raw
data are given in S14 Fig. AAV, adeno-associated virus; EF, ejection fraction; FS, fractional
shortening; IVS;d, interventricular septum thickness in diastole; LVPW;d, left ventricle poste-
rior wall thickness in diastole.
(TIF)
S3 Fig. Overexpression of constitutively active p38γ and p38δ leads to morphological
changes, fibrosis, and predisposes to a worse cardiac prognosis after MI. Mice were IV
injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38γ/δ
act)
and analyzed at PD14. (A) Representative H&E staining of transverse heart sections (scale bar:
1 mm). (B) H&E staining of heart sections. Scale bar: 50 μm. (C) Masson’s trichrome staining
quantification from heart sections (corresponds to the representative images in Fig 1K). (D)
TnTGFP control mice or TnTp38γ/δact mice (with AAV injection at PD1) were subjected to
MI at PD7 and evaluated after 4 weeks. Echocardiography measurements. Data are
mean ± SEM (n = 4–10). ��p< 0.01; ���p< 0.001 by Student t test. Raw data are given in S14
Fig. AAV, adeno-associated virus; FS, fractional shortening; H&E, hematoxylin and eosin;
IVS;d, interventricular septum thickness in diastole; LVID;d, left ventricular internal diameter
in diastole; LVPW;d, left ventricle posterior wall thickness in diastole; MI, myocardial infarc-
tion; WT, wild-type.
(TIF)
S4 Fig. Cardiac-specific p38γ/δact overexpression decreases glycolysis but does not alter
expression of enzymes involved in lipid metabolism or mitochondrial function. Mice were
IV injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38/
δact) and killed at PD14. (A) Immunoblot expression analysis of lipid metabolic enzymes in
cardiac tissue with its respective quantification. (B) Cardiac mitochondrial to chromosomal
DNA ratio. (C) Immunoblot of mitochondrial complexes in heart lysates. (D) Cardiac mito-
chondrial ATP production, measured upon exposure to glutamate plus malate or free fatty
acids. (E) qRT-PCR of enzymes involved in cardiac lipid metabolism. Data are mean ± SEM
(n = 10–15). �p< 0.05, ���p< 0.001 by Student t test. Raw data are given in S14 Fig. qRT-PCR,
real-time quantitative PCR.
(TIF)
S5 Fig. Cardiac-specific p38γ/δact overexpression have impact on whole-body composition
and lead to WAT lipolysis with no significant changes in liver metabolic enzymes. Mice
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were IV injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact
(TnTp38/δact) and analyzed at PD14. (A) Immunoblot analysis of FAS, p-AMPK, AMPK, and
vinculin (load control) in hepatic lysates. Right panel, quantification. (B) Immunoblot analysis
of PKA, p-HSL, HSL, p-AMPK, AMPK, p-ACC, ACC, p-p38, and vinculin (load control) in
WAT lysates. Right panel, quantification. (C) Body weight. (D) MRI-estimated fat and lean
mass. (E) Plasma insulin. Data are mean ± SEM. (n = 4–20). �p< 0.05; ��p< 0.01;
���p< 0.001 by Student t test. Raw data are given in S14 Fig. WAT, white adipose tissue.
(TIF)
S6 Fig. Immunoblot quantification of Fig 4C. Mice were IV injected at PD1 with AAV-
cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact (TnTp38/δ
act) and killed at PD14. Immu-
noblot quantification is shown for (A) heart (p-AKT/Vinculin, p38γact/Vinculin and p38δact/
Vinculin), (B) liver (p-AKT/Vinculin), (C) muscle (p-AKT/Vinculin), and (D) WAT (p-AKT/
Vinculin). Data are mean ± SEM (n = 3 or 4). �p< 0.05, ��p< 0.01, ���p< 0.001 by ANOVA
coupled to Tukey posttest. Raw data are given in S14 Fig. WAT, white adipose tissue.
(TIF)
S7 Fig. Muscle-specific p38γ/δact overexpression after birth does not alter whole-body
metabolism. Mice were IV injected at P1 with AAV-Myf4-EGFP (Myf4-EGFP) or AAV-
Myf4-p38γ/δact (Myf4-p38γ/δ
act) and analyzed at PD14. (A) Immunoblot analysis of p38γ/δact
in muscle extracts. (B) Plasma glucose in fed or 4-h food-deprived mice. (C) GTT and ITT.
Data are mean ± SEM (n = 7–9). Two-way ANOVA coupled to Tukey posttest. Raw data are
given in S14 Fig. GTT, glucose tolerance test; ITT, insulin tolerance test.
(TIF)
S8 Fig. Metabolic alterations precede the onsets of cardiac defects in TnTp38γ/δact mice.
Mice were IV injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-p38γ/δact
(TnTp38γ/δact), and metabolic tests were performed at PD7. (A) HWTL ratio. (B) Representa-
tive images of Masson’s trichrome staining of transverse heart sections (left) and quantification
(right). Scale bar: 200 μm. (C) Representative images of PAS staining from heart sections (left)
and quantification (right). Scale bar: 200 μm. (D) Cardiac glycogen content. (E) Left ventricle
FS measured by echocardiography. (F) Blood glucose levels. (G) Plasma levels of triglycerides
and NEFA. Data are mean ± SEM (n = 4–5). �p< 0.05; ��p< 0.01 by Student t test. Raw data
are given in S14 Fig. FS, fractional shortening; HTWL, heart weight to tibia length; NEFA,
non-esterified fatty acid; PAS, periodic acid–Schiff.
(TIF)
S9 Fig. Cardiac-specific overexpression of p38γ/δact decreases exercise capacity in adult-
hood. Mice were IV injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP) or AAV-cTnT-
p38γ/δact (TnTp38γ/δ
act) and analyzed at 12 weeks. (A) Immunoblot quantification of Fig 5A
expressed as relative protein levels of exogenous active (p38γact) to endogenous p38γ. (B) Exer-
cise capacity was analyzed by measuring maximal distance and exercise duration until exhaus-
tion. Data are mean ± SEM (n = 4–5). �p< 0.05 by Student t test. Raw data are given in S14
Fig.
(TIF)
S10 Fig. Immunoblot analysis of p-PKA C (Thr197) in heart lysates of TNTGFP and
TNTp38γ/δact mice.
(TIF)
S11 Fig. GYS1, a new phosphorylation target of p38γ and p38δ. (A) In an in vitro kinase
assay, recombinant human GYS1 protein (2 μg) was incubated alone or in the presence of
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active recombinant p38γ or p38δ, or both, with 0.2 mM of cold ATP for 60 min. The table
shows the GYS1 residues phosphorylated by p38γ, p38δ, or both. Data are representative of at
least 3 independent experiments. (B, C) In an in vivo kinase assay, HEK-293 cells were trans-
fected with p38γ, p38δ, or both, and GYS1 was immunoprecipitated to obtain the MS/MS
spectra. GYS1 phosphorylated sites are indicated in red. The table shows the GYS1 residues
phosphorylated by p38γ, p38δ, or both. No phosphopeptides were identified when HEK-293
cell were transfected with an empty vector without kinase. Raw data are given in S14 Fig.
GYS1, glycogen synthase 1.
(TIF)
S12 Fig. Cardiac-specific p38γact or p38δact overexpression alone is not sufficient to alter
either whole-body metabolism or cardiac glycogen deposition. Mice were IV injected at
PD1 with AAV-cTnT-GFP-Luc (TnTGFP), AAV-cTnT-p38γact (TnTp38γ
act), or AAV-cTnT-
p38δact (TnTp38δact) and killed at PD14. (A) Immunoblot analysis of GYS1 phosphorylation
at the GSK3 canonical site, S641. (B) Representative images of Masson’s trichrome and PAS
staining on transverse heart sections. Scale bar: 200 μm. (C) Plasma glucose. (D) GTT and
ITT. (E) Plasma NEFA and triglycerides. Data are mean ± SEM (n = 10) ���p<0.001 by one-
way or two-way ANOVA coupled to Tukey posttest. Raw data are given in S14 Fig. GSK3, gly-
cogen synthase kinase-3; GTT, glucose tolerance test; GYS1, glycogen synthase 1; ITT, insulin
tolerance test; NEFA, non-esterified fatty acid; PAS, periodic acid–Schiff.
(TIF)
S13 Fig. Maternal HFD feeding has almost no effects on cardiac and thermogenic capacity
in TNT-GFP mice. CD1 females were crossed; after pregnancy confirmation by vaginal plug
appearance, they were fed a HFD for the entire experiment (e.g., pregnancy and lactation).
Neonates were IV injected at PD1 with AAV-cTnT-GFP-Luc (TnTGFP); during their lacta-
tion, mother remained on the same diet (e.g., ND or HFD) as during pregnancy. Pups were
killed at PD14 and analyzed. (A) Percentage of mice at PD14 with normal or abnormal mitral
valve flow (E/A) as an indicator of diastolic dysfunction. (B) Echocardiography measured
parameters. (C) LVID,d. (D) BAT temperature chart from mice at PD14. Data are
mean ± SEM (n = 9 or 10). ��p< 0.01 by Student t test or chi-squared test. Raw data are given
in S14 Fig. BAT, brown adipose tissue; FS, fractional shortening; HFD, high-fat diet; LVID,d,
left ventricular internal diameter in diastole; LV mass, left vetricular mass; LV Vol, d, left ven-
tricular volume in diastole; ND, normal diet.
(TIF)
S14 Fig. Excel spreadsheet with raw data from all figures.
(XLSX)
S15 Fig. Raw western blot images.
(PDF)
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lez-Terán, Guadalupe Sabio.
Methodology: Ayelén M. Santamans, Valle Montalvo-Romeral, Alfonso Mora, Juan Antonio
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